Jana Linhartová

Monitoring of childhood ALL using BCR-ABL1 genomic breakpoints identifies a subgroup with CML-like biology

Lenka Hovorková, Markéta Žaliová, Nicola C. Venn et al. · Blood · 2017 · 134 citations · Full text

Life Sciences, Genetics, Pediatrics +7

Next-generation deep sequencing improves detection of BCR-ABL1 kinase domain mutations emerging under tyrosine kinase inhibitor treatment of chronic myeloid leukemia patients in chronic phase

Kateřina Machová Poláková, Vojtěch Kulvait, Adela Benesova et al. · Journal of Cancer Research and Clinical Oncology · 2014 · 78 citations · Full text

Medicine, Hematology, Oncology +13

Next-generation sequencing for sensitive detection of <i>BCR-ABL1</i> mutations relevant to tyrosine kinase inhibitor choice in imatinib-resistant patients

Simona Soverini, Caterina De Benedittis, Kateřina Machová Poláková et al. · Oncotarget · 2016 · 61 citations · Full text

Medicine, Hematology, Oncology +16

Exosomes released by imatinib‑resistant K562 cells contain specific membrane markers, IFITM3, CD146 and CD36 and increase the survival of imatinib‑sensitive cells in the presence of imatinib

Tereza Hrdinova, Ondřej Toman, Jiří Dresler et al. · International Journal of Oncology · 2020 · 32 citations · Full text

Life Sciences, Cell Biology, Molecular Biology +17

In chronic myeloid leukemia patients on second-line tyrosine kinase inhibitor therapy, deep sequencing of BCR-ABL1 at the time of warning may allow sensitive detection of emerging drug-resistant mutants

Simona Soverini, Caterina De Benedittis, Fausto Castagnetti et al. · BMC Cancer · 2016 · 29 citations · Full text

Medicine, Oncology, Pharmacology +13